{"id":"NCT03428100","sponsor":"Eli Lilly and Company","briefTitle":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable","officialTitle":"A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-15","primaryCompletion":"2019-11-25","completion":"2023-04-20","firstPosted":"2018-02-09","resultsPosted":"2021-01-19","lastUpdate":"2024-05-14"},"enrollment":463,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Baricitinib","otherNames":["LY3009104"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Topical corticosteroid","otherNames":[]}],"arms":[{"label":"4 mg Baricitinib","type":"EXPERIMENTAL"},{"label":"2 mg Baricitinib","type":"EXPERIMENTAL"},{"label":"1 mg Baricitinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Long Term Extension(LTE) Substudy 4mg Baricitinib to 4mg Baricitinib (Responders/Partial Responders)","type":"EXPERIMENTAL"},{"label":"LTE Substudy 4 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)","type":"EXPERIMENTAL"},{"label":"LTE Substudy 2 mg Baricitinib to 2 mg Baricitinib (Responders/Partial Responders)","type":"EXPERIMENTAL"},{"label":"LTE Substudy 2 mg Baricitinib to 1 mg Baricitinib (Responders/Partial Responders)","type":"EXPERIMENTAL"},{"label":"LTE 4 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 2 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 1 mg Baricitinib (Responders/Partial Responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE Placebo (Responders/Partial Responders) - Did Not Enter Substudy","type":"PLACEBO_COMPARATOR"},{"label":"LTE 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 2 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 2 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 1 mg Baricitinib to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE 1 mg Baricitinib to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE Placebo to 2 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"},{"label":"LTE Placebo to 4 mg Baricitinib (Non-responders) - Did Not Enter Substudy","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of baricitinib in combination with topical corticosteroids in participants with moderate to severe atopic dermatitis who have experienced failure to cyclosporine or are intolerant to, or have contraindication to cyclosporine.","primaryOutcome":{"measure":"Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib)","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":17.2,"sd":null},{"arm":"2 mg Baricitinib","deltaMin":27.6,"sd":null},{"arm":"4 mg Baricitinib","deltaMin":31.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.071"},{"comp":"OG000 vs OG002","p":"0.031"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":103,"countries":["Austria","Belgium","Brazil","Finland","France","Germany","Italy","Japan","Netherlands","Poland","Russia","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":["36255569","33826132"],"seeAlso":["https://www.lillytrialguide.com/en-US/studies/eczema/JAIN#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":93},"commonTop":["Nasopharyngitis","Headache","Influenza","Covid-19","Oral herpes"]}}